HCV therapy with daclatasvir, PEG-IFN, and RBV after boceprevir-based therapy failure post-liver transplantation in hyper-IgM syndrome

Transplantation

Volumn 97, Issue 8, 2014, Pages

  Reddy, K Rajender ^a   Wirjosemito, Amina ^a   Pavri, Tanya M ^a   Sinese, Lorie ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; HYPER-IGM IMMUNODEFICIENCY SYNDROME; IMIDAZOLES; IMMUNOGLOBULIN M; INTERFERON-ALPHA; LIVER TRANSPLANTATION; MALE; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84899090382     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000076     Document Type: Letter

References (10)

1. Watt K, Veldt B, Charlton M. A practicalguide to the management of HCV infectionfollowing liver transplantation. Am J Transplant2009; 9: 1707.
2. Narang TK, Ahrens W, Russo MW. Postlivertransplant cholestatic hepatitis C: asystematic review of clinical and pathologicalfindings and application of consensuscriteria. Liver Transpl 2010; 16: 1228.
3. Smith MS, Webster AD, Dhillon AP, et al.Orthotopic liver transplantation for chronichepatitis in two patients with common variableimmunodeficiency. Gastroenterology1995; 108: 879.
4. Lok AS, Gardiner DF, Lawitz E, et al. Preliminarystudy of two antiviral agents forhepatitis C genotype 1. N Engl J Med 2012;366: 216.
5. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvirfor previously treated or untreated chronicHCV infection. N Engl J Med 2014;370: 211.
6. Fontana RJ, Hughes EA, Appelman H, et al.Case report of successful peginterferon,ribavirin, and daclatasvir therapy for recurrentcholestatic hepatitis C after liverretransplantation. Liver Transpl 2012;18: 105.
7. Fontana RJ, Hughes EA, Bifano M, et al.Sofosbuvir and daclatasvir combinationtherapy in a liver transplant recipient withsevere recurrent cholestatic hepatitis C. AmJ Transplant 2013; 13: 160.
8. Sarrazin C, Kieffer TL, Bartels D, et al.Dynamic hepatitis C virus genotypic andphenotypic changes in patients treated withthe protease inhibitor telaprevir. Gastroenterology2007; 132: 1767.
9. Fridell RA, Wang C, Sun JH, et al. Genotypicand phenotypic analysis of variantsresistant to hepatitis C virus nonstructuralprotein 5A replication complex inhibitorBMS-790052 in humans: in vitro andin vivo correlations. Hepatology 2011;54: 1924.
10. Pearlman BL. Protease inhibitors for thetreatment of chronic hepatitis C genotype-1 infection: the new standard of care.Lancet Infect Dis 2012; 12: 717.